<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574975</url>
  </required_header>
  <id_info>
    <org_study_id>ZhujiangH</org_study_id>
    <nct_id>NCT02574975</nct_id>
  </id_info>
  <brief_title>Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics</brief_title>
  <official_title>Comparison of Different Methodologies Assessing Airway Responsiveness and Investigation of Treatment Efficacy of Budesonide /Formoterol in Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchial asthma is a common chronic respiratory disease. Patients usually manifest variable
      symptoms (such as short of breath, chest tightness, cough, etc.) and variable airflow
      limitation and often associated with airway hyper-responsiveness and airway inflammation.
      About 1-18% of the global population suffered from the disease, causing huge economic burden
      for patients and countries. Airway reactivity measurement is an important way of diagnosis of
      asthma. Methacholine (Mch) bronchial provocation test(BPT) is the &quot;gold standard&quot; for the
      determination of airway reactivity, and other measuring methods(like adenosine
      monophosphate(AMP)-BPT, leukotriene D4(LTD4)-BPT, Astograph-BPT, etc.) were also brought into
      hot research fields. The investigators' purposes were to compare different kinds of
      methodologies(Mch,AMP,LTD4-BPT, Astograph-BPT) assessing airway responsiveness and to
      investigate treatment efficacy of budesonide /formoterol in asthmatics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study composed of two parts, that were the diagnosing part and the treatment part.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positive rate of BPT in each group</measure>
    <time_frame>3months</time_frame>
    <description>comparing positive rates of BPT in experimental groups and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume at one second（FEV1）</measure>
    <time_frame>3months</time_frame>
    <description>change of FEV1 measured by pulmonary function test（PFT）at one month interval for 3 consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional exhaled nitric oxide(FeNO)</measure>
    <time_frame>3months</time_frame>
    <description>change of FeNO at one month interval for 3 consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provocative dosage causing a 20% fall in FEV1(PD20-FEV1)</measure>
    <time_frame>3months</time_frame>
    <description>change of PD20-FEV1 at one month interval for 3 consecutive months in each group</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Methacholine diagnosing group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adenosine monophosphate diagnosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leukotriene D4 diagnosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astograh diagnosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>budesonide /formoterol treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methacholine</intervention_name>
    <description>Methacholine,inhaled cumulative dosage 2.5mg</description>
    <arm_group_label>Methacholine diagnosing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine monophosphate</intervention_name>
    <description>Adenosine monophosphate ,inhaled cumulative dosage 40mg</description>
    <arm_group_label>Adenosine monophosphate diagnosing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leukotriene D4</intervention_name>
    <description>Leukotriene D4,inhaled cumulative dosage 2.4 μg</description>
    <arm_group_label>Leukotriene D4 diagnosing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Astograph Jupiter-21 airway reaction testing apparatus</intervention_name>
    <description>Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus</description>
    <arm_group_label>Astograh diagnosing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide /formoterol</intervention_name>
    <description>budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)</description>
    <arm_group_label>budesonide /formoterol treatment group</arm_group_label>
    <other_name>Symbicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed Asthmatic patients aged from14 to 65 years；

          -  Had a had a normal chest radiographic result；

          -  Had a baseline spirometry with the forced expiratory volume in one second (FEV1) of
             not less than 60% predicted；

          -  Without acute upper respiratory tract infection for the past 2 weeks

        Exclusion Criteria:

          -  Smokers；

          -  Had a poor cooperation to the test or limited understandings;

          -  Had a past confirmed history of respiratory disease other than bronchial asthma (COPD,
             bronchiectasis, pulmonary thromboembolism, etc.) or other severe systemic
             disease（myocardial infarction, malignant tumor, etc.）;

          -  Pregnancy or breast-feeding women;

          -  Taken related drugs before measurements（Leukotriene receptor antagonists (LTRA) for 5
             days，oral glucocorticosteroid or anti-histamine for 3 days，oral xanthenes or
             long-acting bronchodilators for 2 days，inhaled corticosteroid or long-acting
             bronchodilator for a day , short-acting bronchodilator for 4 hours ）
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huizhen Fan, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Zhujiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuhan Wu, Master</last_name>
    <phone>13268268627</phone>
    <email>664397041@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhan Wu, Master</last_name>
      <phone>13268268627</phone>
      <email>664397041@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

